Investor Relations

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology that address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid  represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissues.

  • Intra
  • 3 mo.
  • 6 mo.
  • 1 yr.

Press Releases

  • May 17, 2022
    Ofer Gonen , current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka , who will join the Board of Directors YAVNE, Israel , May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
  • May 17, 2022
    Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds On track for NexoBrid BLA resubmission by mid-year Conference C all B egins T oday at 8:30 am ET   YAVNE, Israel , May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.

Events & Presentations

Investor Presentation

mediwound image